Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial will combine fludarabine, rituximab, and lenalidomide in untreated or
minimally treated (Phase I only) CLL patients, employing fixed doses of fludarabine and
rituximab, using a schedule similar to that examined by investigators at MD Anderson (J Clin
Oncol 23(18):4079-88, 2005). Given that the optimal dose and schedule is not currently known,
this trial will perform a phase I component followed by a phase II examination to further
explore this regimen's activity.